I think the ONXX MM data will be quite helpful for them with the FDA. They show some clear responses (about 20% PRs or better with an 8 month duration) in patients refractory to any and all available therapies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.